Latest Breaking News On - Products clinical trials grants program - Page 5 : vimarsana.com

Share this article Share this article PHILADELPHIA, and BIRMINGHAM, Ala., April 12, 2021 /PRNewswire/  Treovir, an immuno-oncology company that is developing and plans to commercialize G207 for recurrent glioblastoma in children, announced today that G207, an oncolytic HSV immunotherapy, was well tolerated with evidence of clinical effectiveness in a phase 1 study of 12 pediatric patients with recurrent high-grade glioma.  Data from the phase 1 study (NCT02457845) are being presented by Gregory Friedman, M.D., professor in the Department of Pediatrics at the University of Alabama at Birmingham, during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15.  Data from this trial have been published in the

United statesUniversity of alabama at birminghamGregory friedmanMichael christiniDave schemeliaG yancey gillespieFoundation for childhood cancer researchCannonball kid cancer foundationBaldrick foundationKaul pediatric research instituteProducts clinical trials grants programDepartment of pediatricsPediatric brain tumor consortiumNew england journalPrincipal investigatorRally foundation